Continuous NMB in PCAS

Continuous Neuromuscular Blocking Agent for out-of Hospital Cardiac Arrest; Multicenter Randomized Controlled Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02790164

Enrollment

Registered

2016-06-03

Start date

2016-05-31

Completion date

Unknown

Last updated

2016-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Out-of-hospital Cardiac Arrest

Brief summary

The main purpose of this study is to test the hypothesis that continuous NMB could improve outcome in cardiac arrest patients treated with therapeutic hypothermia.

Interventions

DRUGEsmeron

Neuromuscular Blockade

DRUGSaline

Normal Saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult (older than 19) 2. OHCA with sustained ROSC 3. Comatose (i.e., not following commands) following ROSC 4. Undergoing targeted temperature management (TTM) 5. Time of enrollment ≤ 6hrs from ROSC

Exclusion criteria

1. Pre-existing dementia, brain injury, or dependence on others for ADLs (CPC \> 3) 2. Traumatic etiology for cardiac arrest 3. Protected population (pregnant, prisoner)

Design outcomes

Primary

Measure	Time frame
Lactate levels 24 hours after initiation of study drug	24 hours

Secondary

Measure	Time frame	Description
Lactate change over time	0, 12, 24, 36 hrs	—
Survival	Duration of hospitalization, limit 180 days	in-hospital survival
Good neurological outcome	Duration of hospitalization, limit 180 days	Modified Rankin Scale
Length of intensive care unit stay	Duration of ICU stay, limit 180 days	—

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026